Weinstein et al. GO-BACK. Another TNFi withdrawal study in nr-axSpA. Again showing it doesn't work. 12 months. Only 34% of withdrawal group in remission vs 84% full dose and 68% reduced dose group. @RheumNow #ACR22 Abstr#0545 https://t.co/Fa5YgT9FYk https://t.co/9C8ShI9qjk

• Continuing (Full or Reduced Treatment) versus Withdrawing from Golimumab Treatm…

Day 2: Tips to avoid burnout. I know it’s Sunday morning but a dose of #physicalactivity will keep the mind and body sane. Dare to accept challenge? #ACRVirtual5K Run #ACR22 #rheumatologyrunners #wellbeing #foggy @RheumNow #RheumPix https://t.co/N9ulz8KPVw

Broder et al. HCQ alone vs steroid alone as maintenance in ESKD due to SLE. HCQ less cardiac events, less infection. @RheumNow #ACR22 Abstr#0539 https://t.co/mb3Eof2Uiv https://t.co/3i3ZTY25ru

• Cardiac Complications, Thrombosis, Infections and All-cause Mortality Among Pat…

Rech et al. 18 month results of ARIAA, 6 months abatacept in pre-RA, 1 year drug-free follow-up. 35% vs 65% developed RA. MRI response 57% vs 29%. @RheumNow #ACR22 Abstr#0530 https://t.co/35M2sPkIbW https://t.co/S8K39jkCh0

• You searched for 0530 - ACR Meeting Abstracts

Ab0675 #ACR22 DAH in APLS 61 pts w APS, incident DAH 85% h/o VTE, 51% thrombocyt 43% valvulopathy 74% were on a/c at time of DAH Relapse rate: 41% at 1 yr, 26% w/in 6 mos!!! Risks: triple pos, thrombocyt, IVIG, PLEX, ventilation Mortality 19% 1 yr, 38% 5 yrs @RheumNow #ACRBest https://t.co/g1uz2Giilc

Ab0676 #ACR22 Adrenal hemorrhage in APLS 59 pts from SLE cohort + 181 from lit review 65% prior VTE, 12% CVA, 24% OB morbidity 46% thrombocyt, 21% had SLE 58% on a/c 69% b/l hemorrhage 63% adrenal insuff Radiol remission: 6% at 1 yr, 41% at 5yr Death 2% 1 yr, 11% at 5 @RheumNow https://t.co/EacifcN7Sd

Ab0683 #ACR22 aPL Pts ANA pos vs neg: 521 pts with +aPL Ab WO other autoimmune disease 224 +ANA, 297 -ANA ANA+ ass w/ hemolytic anemia, thrombocyt, leukopenia, livedo, unexplained fetal death Trend for arthritis, aPL nephropathy @RheumNow https://t.co/3NHGymyL1C

Ab0685 #ACR22 APLS and prior COVID infection TKR patients at HSS: 1/5 of patients had positive aPL Ab, mostly low level aCL IgM Not associated with COVID infection or SARS-CoV-2 Ab @RheumNow https://t.co/HJpnUOrrxc

Schieir et al. Women with early RA less likely to achieve remission. 12 months 37% vs 43%. 4 years 61% vs 64%. Time to remission 19 months vs 16 months. @RheumNow #ACR22 Abstr#0532 https://t.co/ZRuqqaPHHU https://t.co/pDBHHtLEhs

• Women with Early Rheumatoid Arthritis Less Likely to Achieve Rapid and Sustaina…

🧨Late breaking abstract🧨 #ACR22 @RheumNow #ACRbest Identifying fetal myocardial targets in congenital heart block (CHB) Abstract #L13 🫀maternal serum underwent mass spec. that identified Ab to 4 protein targets that predicted CHB including anti-ATP1A1 as early as 7w

Porter et al. Asymptomatic Pre-RA to symptomatic Pre-RA to early RA steady increase in bacterial infection compared to HC. Causality or Reverse Causality? I think more likely reverse - disease related immunosuppresion @RheumNow #ACR22 Abstr#0535 https://t.co/i5iN3Db7rf https://t.co/2ynYF7Vqbl

• Increase Rates of Bacterial Infection in Patients with 'Pre-RA' - ACR…

Ab0674 #ACR22 HIT AND APLS?? Retrosp review of 23 pts treated for HIT in the hospital with APLS or SLE with aPL Ab: Not one ultimately met clinical criteria for HIT 1 pt had PF4 antibodies, SRA testing negative in ALL cases Thrombocytopenia w/ aPL Abs? Think APS 1st! @Rheumnow https://t.co/ZYZP5VZF0R

Ab0673 #ACR22 Occurrence & Severity of ITP w or w/o APLS antibodies Fewer bleeding events in ITP patients w/ aPL antibodies (15% vs 43%) compared to w/o aPL antibodies Despite more use of a/c and lower median patients in aPL patients Is aPL Ab a good prognosis for ITP? @RheumNow https://t.co/yLBVUN2T0L

Hear Dr. @AngusWorthing discuss advocacy and more legislative updates at #ACR22 @RheumNow https://t.co/zD8xpcCzi2

• What's Happening on the Hill? | RheumNow

IL17A/Fi BImekizumab BKZ to Wk 24 achieved reduction in ◦ total spinal pain (SP) ◦ nocturnal SP ◦ morning stiffness (BASDAI) ◦ fatigue (FACIT-F) Deodhar et al, BE MOBILE 1,2 Abst 0409 https://t.co/vpCrG2COuB #ACR22 @RheumNow

• Bimekizumab Improves Key Patient Reported Symptoms of Axial Spondyloarthritis I…